Zydus Lifesciences share price remained unchanged in the opening trade on October 27 following the NOC (Notice of Compliance) from Health Canada for generic Mesalamine suppositories 1000 mg.
At 09:24am, Zydus Lifesciences was quoting at Rs 1,004.95, down Rs 0.70, or 0.07 percent, on the BSE.
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.
ZDS - Mesalamine suppositories will be manufactured at company's Changodar, Ahmedabad in Gujarat, India.
Catch all the market action on our live blog
Earlier in this month, the company received NOC from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg, use for treating hypothyroidism.
Also, received final approval from the United States Food and Drug Administration (USFDA) for Deflazacort oral suspension.
In the previous trading session, the share closed at Rs 1,005.65, down Rs 2.15, or 0.21 percent.
The share touched a 52-week high of Rs 1,059.00 and a 52-week low of Rs 797.05 on 19 September, 2025 and 07 April, 2025, respectively.
Currently, the stock is trading 5.1 percent below its 52-week high and 26.08 percent above its 52-week low.
The market capitalisation of the company stands at Rs 101,121.48 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
